Botulinum neurotoxin: a marvel of protein design
- PMID: 20233039
- DOI: 10.1146/annurev.biochem.051908.125345
Botulinum neurotoxin: a marvel of protein design
Abstract
Botulinum neurotoxin (BoNT), the causative agent of botulism, is acknowledged to be the most poisonous protein known. BoNT proteases disable synaptic vesicle exocytosis by cleaving their cytosolic SNARE (soluble NSF attachment protein receptor) substrates. BoNT is a modular nanomachine: an N-terminal Zn(2+)-metalloprotease, which cleaves the SNAREs; a central helical protein-conducting channel, which chaperones the protease across endosomes; and a C-terminal receptor-binding module, consisting of two subdomains that determine target specificity by binding to a ganglioside and a protein receptor on the cell surface and triggering endocytosis. For BoNT, functional complexity emerges from its modular design and the tight interplay between its component modules--a partnership with consequences that surpass the simple sum of the individual component's action. BoNTs exploit this design at each step of the intoxication process, thereby achieving an exquisite toxicity. This review summarizes current knowledge on the structure of individual modules and presents mechanistic insights into how this protein machine evolved to this level of sophistication. Understanding the design principles underpinning the function of such a dynamic modular protein remains a challenging task.
Similar articles
-
Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.Nature. 2006 Dec 21;444(7122):1092-5. doi: 10.1038/nature05387. Epub 2006 Dec 13. Nature. 2006. PMID: 17167421
-
Engineered botulinum neurotoxins as new therapeutics.Annu Rev Pharmacol Toxicol. 2014;54:27-51. doi: 10.1146/annurev-pharmtox-011613-135935. Epub 2013 Aug 30. Annu Rev Pharmacol Toxicol. 2014. PMID: 24016211 Review.
-
Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.Toxicon. 2013 Dec 1;75:108-21. doi: 10.1016/j.toxicon.2013.06.010. Epub 2013 Jun 29. Toxicon. 2013. PMID: 23817019
-
Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin.Prog Biophys Mol Biol. 2015 Mar;117(2-3):225-231. doi: 10.1016/j.pbiomolbio.2015.02.004. Epub 2015 Feb 19. Prog Biophys Mol Biol. 2015. PMID: 25701633 Free PMC article. Review.
-
Identification and characterization of a novel botulinum neurotoxin.Nat Commun. 2017 Aug 3;8:14130. doi: 10.1038/ncomms14130. Nat Commun. 2017. PMID: 28770820 Free PMC article.
Cited by
-
Plasma membrane flipping of Syntaxin-2 regulates its inhibitory action on insulin granule exocytosis.Nat Commun. 2022 Oct 31;13(1):6512. doi: 10.1038/s41467-022-33986-3. Nat Commun. 2022. PMID: 36316316 Free PMC article.
-
Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH.Biochemistry. 2012 Jul 17;51(28):5655-62. doi: 10.1021/bi3004928. Epub 2012 Jul 2. Biochemistry. 2012. PMID: 22720883 Free PMC article.
-
Botulinum neurotoxin is shielded by NTNHA in an interlocked complex.Science. 2012 Feb 24;335(6071):977-81. doi: 10.1126/science.1214270. Science. 2012. PMID: 22363010 Free PMC article.
-
The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.Cell Mol Life Sci. 2014 Mar;71(5):793-811. doi: 10.1007/s00018-013-1380-7. Epub 2013 Jun 11. Cell Mol Life Sci. 2014. PMID: 23749048 Free PMC article. Review.
-
The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.Clin Vaccine Immunol. 2013 Aug;20(8):1266-73. doi: 10.1128/CVI.00268-13. Epub 2013 Jun 12. Clin Vaccine Immunol. 2013. PMID: 23761665 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases